Novo Nordisk (NVO) Announces Positive Early Response Data from Oral Wegovy (25 mg) Trial

Novo Nordisk (NYSE:NVO) is one of the cheap stocks to buy for the next 10 years. On May 13, Novo Nordisk presented new data from the OASIS 4 clinical trial at the European Congress on Obesity 2026, highlighting the effectiveness of the oral Wegovy pill (25 mg). The findings reveal that nearly one-third of participants were early responders, achieving a 13.2% weight loss within the first four months and reaching an average of 21.6% by the end of the 64-week study. Even those who did not meet early response criteria still achieved a clinically meaningful weight loss of 11.5%.

Beyond weight reduction, the treatment showed significant benefits for physical function and mobility. Nearly 80% of participants who started the trial with poor physical function reported nearly double the improvement in their ability to move, stand, and stay active compared to the placebo group. These quality-of-life improvements were seen alongside a safety profile consistent with the GLP-1 receptor agonist class, with most side effects being mild to moderate gastrointestinal issues.

Pixabay/Public Domain

Comparative analyses also positioned the Wegovy pill favorably against competitors like orforglipron. Research indicated that the pill delivered superior weight loss results and had significantly lower odds of treatment discontinuation due to side effects. Currently, the oral 25 mg dose is FDA-approved and pending regulatory approval in other markets, expanding the options for long-term weight management and cardiovascular risk reduction.

Novo Nordisk (NYSE:NVO) is a drug manufacturer for global pharmaceutical products that operates through two segments: Obesity & Diabetes Care and Rare Disease. The company was founded in 1923 and is headquartered in Denmark.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.